Anti-CD16-anti-CD30 monoclonal antibodyAlternative Names: Anti-CD16-anti-CD30 bispecific monoclonal antibody; Anti-CD30-anti-CD16 bispecific monoclonal antibody; Anti-CD30-anti-CD16 monoclonal antibody
Latest Information Update: 22 Mar 2007
At a glance
- Originator Biotest
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Lymphocyte stimulants; Natural killer cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hodgkin's disease